- Atopic dermatitis, or eczema, affects about 3% of adults and 20% of children around the world.
- Researchers from the Institute of Plasma Physics Chinese Academy of Sciences used a mouse model to show that cold atmospheric plasma (CAP) to be a potential treatment for atopic dermatitis with little to no side effects.
- Experts see CAP as having a “great deal of promise” as a future treatment option.
There is currently no cure for atopic dermatitis. Instead, doctors
Now, a team of researchers from the Institute of Plasma Physics Chinese Academy of Sciences says cold atmospheric plasma can be added to the list of treatment options for this skin condition.
This study, which used a mouse model, was recently published in the journal Frontiers in Immunology.
According to Dr. Guohua Ni, a lead author of the new study and a professor at the Institute of Plasma Physics Chinese Academy of Sciences, the main purpose behind the recent research was to find an effective therapy with fewer side effects for the treatment of atopic dermatitis and other skin diseases.
“At present, atopic dermatitis therapy is mainly based on
What makes CAP a viable treatment option for atopic dermatitis?
“CAP has been widely involved in medical applications,” Ni said. “CAP is able to promote acute and chronic wound healing, improve oral cleaning and disinfection, and facilitate cancer treatment. It has been demonstrated that CAP up-regulates the expression of hypoxia-inducible factor-1 (HIF-1) in human dermal fibroblasts. This provides a possibility for the effective treatment of [atopic dermatitis] by CAP therapy.”
During the study, Ni and his team said they found the CAP treatment helped heal atopic dermatitis-like skin injuries in a mouse model. Additionally, the CAP treatment helped alleviate skin inflammation,
As for potential side effects, Ni said previous studies have shown that CAP therapy is safe with minimal to no side effects.
“Although we did not investigate the side effects in the present work, we believe the CAP method is safe with less (or) even no side effects in the treatment of atopic dermatitis,” he added.
MNT also spoke with Dr. Angela J. Lamb, an associate professor of dermatology at the Icahn School of Medicine in New York and vice chair of clinical strategy and operations, dermatology at Mount Sinai in New York.
She said this is an exciting time for atopic dermatitis research.
“Cold atmospheric plasma shows a great deal of promise, and while this is a mouse study, there have been studies in humans that showed improvement in atopic dermatitis for patients treated with CAP,” she explained. “What is nice about this study is that it is well controlled and shows at a molecular level why CAP helps atopic dermatitis.”
“This study elucidates that CAP increases
Ni said he hoped this research will help advance the clinical application of CAP therapy and provide new ideas for the treatment of atopic dermatitis.
“In the next step, we will further investigate the safety and efficacy of CAP technology in the treatment of dermatitis, and promote its clinical application as soon as possible,” he added.
Lamb added that she would like to see more human studies and specific protocols for treatment, including frequency and time of exposure.
“Lastly, it would be nice to see if this has lasting effects on the skin,” she said. “There are many treatments that only work temporarily. It would be nice to see if this accomplishes some more permanent changes in the skin.”